Mazdutide

Mazdutide (LY3305677/IBI362) is a dual GLP-1/glucagon receptor agonist developed through collaboration between Eli Lilly and Innovent Biologics, with significant clinical development in China. It represents another entry in the dual agonist class targeting both incretin receptors for enhanced metabolic effects.

Like other dual agonists, mazdutide combines GLP-1's effects on appetite suppression and insulin secretion with glucagon's promotion of hepatic lipid oxidation and energy expenditure. The relative activity at each receptor is tuned to optimize the metabolic benefit while minimizing glucagon-related side effects.

Clinical trials have demonstrated substantial weight loss effects, with phase 2 data showing efficacy comparable to other agents in the dual and triple agonist class. Development has particularly focused on the Chinese market, where metabolic disease epidemiology and treatment responses may differ from Western populations.

Mazdutide's development contributes to the growing understanding of how GLP-1 and glucagon receptor co-agonism can be optimized for metabolic disease treatment. Comparison between different dual agonists with varying receptor activity ratios helps elucidate the relative contributions of each pathway to clinical outcomes.